ipilimumab + pembrolizumab + durvalumab + idarubicin + bevacizumab

This is a combination regimen consisting of five distinct anticancer agents: ipilimumab, pembrolizumab, durvalumab, idarubicin, and bevacizumab. - **Ipilimumab** is a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), enhancing T-cell activation and proliferation to promote antitumor immune responses. - **Pembrolizumab** is a humanized monoclonal antibody against programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2 to restore immune surveillance against tumor cells[5][1]. - **Durvalumab** is a human IgG1 kappa monoclonal antibody that binds programmed death-ligand 1 (PD-L1), inhibiting its interaction with PD-1 and CD80 to enhance antitumor immunity[3][9]. - **Idarubicin** is an anthracycline antibiotic chemotherapeutic agent that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis in rapidly dividing cells. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. This combination brings together multiple immunotherapy checkpoint inhibitors with cytotoxic chemotherapy and antiangiogenic therapy. Such regimens are highly experimental; while combinations of two or three of these agents have been studied in various cancers, there are no widely reported clinical trials or approvals for the simultaneous use of all five drugs together.